BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced that it filed a patent application with the U.S. Patent & Trademark Office (USPTO) concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of ANVS401 or related compounds.
“Researchers have noted the similarities between many types of infections of the brain, including infections resulting from COVID-19,” commented Maria Maccecchini, Ph.D., CEO of Annovis Bio. “In fact, autopsies conducted in China have shown the coronavirus to be present in the brain and some people infected with the virus have developed encephalitis and other neurological problems. In addition to our own studies, a number of universities and companies are looking at how viral and bacterial infections (e.g., herpes, HIV, Zika, Lyme disease, gingivitis) cause neurological disorders and neurodegeneration. These short- and long-term neurological problems are caused because invasion of the brain by a virus or bacterium causes levels of neurotoxic proteins to rise, which consequently impairs axonal transport, induces inflammation, and leads to nerve cell death. Because ANVS401 has been shown to protect nerve cells against the ill effects of an increase of neurotoxic proteins in the brain, we believe our compound could help with the treatment of neurological diseases associated with COVID-19 and other infections.”
A brain infection is a bacterial, viral, fungal, protozoan, or parasitic infection of the tissue of the brain itself or the membranes surrounding the brain and spinal cord. Bacteria and viruses are the most common causes of brain infections.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.